Mikołaj Sędzik

Dr. Mikołaj Sędzik

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Cells
Verified
Journal Article
Open access
PDF file
Dominika KunachowiczDominika Kunachowicz
Dominika Kunachowicz
PTPaulina Tomecka
Paulina Tomecka
MSMikołaj Sędzik
Mikołaj Sędzik
JKJarosław Kalinin
Jarosław Kalinin
JKJacek Kuźnicki
Jacek Kuźnicki
NRNina Rembiałkowska
Nina Rembiałkowska
Hypoxia, characterized by a reduction in tissue oxygen levels, is a hallmark of many solid tumors and affects a range of cellular processes, including DNA repair. In low-oxygen conditions, cancer cells often suppress key DNA repair pathways such as homologous recombination (HR), leading to the accumulation of DNA damage and increased genomic instability. These changes not only drive tumor progression but also contribute to resistance against conventional therapies. Hypoxia significantly reduces the effectiveness of oxygen-dependent treatments, including radiotherapy and many chemotherapeutic agents. To address this limitation, bioreductive drugs have been developed that become selectively activated in hypoxic environments, providing targeted cytotoxic effects within oxygen-deprived tumor regions. Additionally, the rapid growth of tumors often results in disorganized and inefficient vasculature, further impairing the delivery of oxygen and therapeutic agents. This review explores the molecular mechanisms by which hypoxia disrupts DNA repair and contributes to treatment resistance. It also presents emerging therapeutic strategies aimed at targeting the hypoxic tumor microenvironment to improve treatment efficacy and patient outcomes.

25 October 2022 in Applied Sciences
Verified
Journal Article
Open access
PDF file
KRKatarzyna Anna Rakoczy
Katarzyna Anna Rakoczy
MKMonika Kisielewska
Monika Kisielewska
MSMikołaj Sędzik
Mikołaj Sędzik
LJLaura Jonderko
Laura Jonderko
JCJulia Celińska
Julia Celińska
Julita KulbackaJulita Kulbacka
Julita Kulbacka
Electroporation (EP) allows for the transport of molecules into the cytoplasm with significant effectiveness by forming transient pores in the cell membrane using electric pulses. This can be used for cellular transport (RE—reversible electroporation) or ablation (IRE—irreversible electroporation). The first of described options fortifies medicine with novel possibilities: electrochemotherapy (ECT), which creates promising perspectives for cancer treatment, and gene electrotransfer (GET), a powerful method of DNA delivery as well as immunogen electrotransfer. The review constitutes a comprehensive explanation of the mechanism of EP in the case of GET, its present and prospective employment in medicine, including gene delivery, vaccinations, therapy, and transfection, are also presented.

18 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NRNina Rembiałkowska
Nina Rembiałkowska
ZKZofia Kocik
Zofia Kocik
AKAmelia Kłosińska
Amelia Kłosińska
MKMaja Magdalena Kübler
Maja Magdalena Kübler
APAgata Pałkiewicz
Agata Pałkiewicz
AGAgnieszka Gajewska-Naryniecka
Agnieszka Gajewska-Naryniecka
Chronic inflammation, while originally a protective physiological response, is increasingly recognized as a key contributor to carcinogenesis. Prolonged inflammatory signaling leads to the sustained production of reactive oxygen and nitrogen species (ROS/RNS), resulting in direct and indirect DNA damage, including base modifications, strand breaks, and DNA cross-linking. Simultaneously, pro-inflammatory mediators such as NF-κB, IL-6, and TNF-α can interfere with DNA repair mechanisms, altering the efficiency of key pathways such as base excision and mismatch repair. Immune cells infiltrating chronically inflamed tissues, including macrophages and neutrophils, further exacerbate genomic instability through ROS/RNS release and cytokine production, creating a tumor-promoting microenvironment. Additionally, chronic inflammation has been implicated in the development of resistance to chemotherapy and radiotherapy by modulating DNA damage response pathways. Understanding the interplay between inflammation, genomic instability, and therapy resistance provides a framework for novel treatment strategies. Targeting chronic inflammation with non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or biological agents such as monoclonal antibodies offers promising avenues for cancer prevention and treatment. Targeting inflammation with NSAIDs, corticosteroids, and monoclonal antibodies shows promise in cancer prevention and therapy, particularly in lung and pancreatic cancer. These agents act by blocking key inflammatory pathways like COX-2, NF-κB, and cytokine signaling. However, potential adverse effects require further clinical evaluation.

3 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
MSMikołaj Sędzik
Mikołaj Sędzik
KRKatarzyna Anna Rakoczy
Katarzyna Anna Rakoczy
JSJakub Jan Sleziak
Jakub Jan Sleziak
Michał KisielMichał Kisiel
Michał Kisiel
KKKarolina Kraska
Karolina Kraska
ACAnna Choromańska
Anna Choromańska
Exosomes and microvesicles bear great potential to broaden therapeutic options in the clinical context. They differ in genesis, size, cargo, and composition despite their similarities. They were identified as participating in various processes such as angiogenesis, cell migration, and intracellular communication. Additionally, they are characterized by their natural biocompatibility. Therefore, researchers concluded that they could serve as a novel curative method capable of achieving unprecedented results. Indeed, in experiments, they proved remarkably efficient in enhancing wound regeneration and mitigating inflammation. Despite immense advancements in research on exosomes and microvesicles, the time for their large-scale application is yet to come. This article aims to gather and analyze current knowledge on those promising particles, their characteristics, and their potential clinical implementations.

9 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NRNina Rembiałkowska
Nina Rembiałkowska
MSMikołaj Sędzik
Mikołaj Sędzik
MKMonika Kisielewska
Monika Kisielewska
WŁWiktoria Łuniewska
Wiktoria Łuniewska
KSKamil Sebastianka
Kamil Sebastianka
Julita KulbackaJulita Kulbacka
Julita Kulbacka
Telomeres are repetitive DNA sequences at the ends of chromosomes that protect against genomic instability and prevent unwanted DNA damage responses. In most somatic cells, telomeres progressively shorten with each division, limiting cellular lifespan. However, cancer cells bypass this limitation by activating telomerase or the alternative lengthening of telomeres, enabling unchecked proliferation and tumor progression. This review examines the molecular mechanisms underlying telomere maintenance and their intricate relationship with DNA repair pathways. We discuss how telomere-associated proteins regulate genomic stability and explore therapeutic strategies targeting telomerase and alternative lengthening of telomeres. Challenges such as resistance mechanisms and off-target effects are also considered, highlighting the need for precision approaches in telomere-based cancer therapies.